As teamLab Planets in Tokyo Welcomes Around 1 Million Visitors From Abroad in a 6-Month Period, the Immersive Museum Unveils the Renewal of Artwork Spaces
31.8.2023 19:00:00 EEST | Business Wire | Press release
teamLab Planets TOKYO DMM ("teamLab Planets"), the body-immersive museum by art collective teamLab in Toyosu, Tokyo, celebrated its fifth anniversary with the renewal of artwork spaces, making it an even more immersive experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830716639/en/
As visitors touch the countless crystals of light floating in the air, the work transforms interactively. On view at teamLab Planets, a body immersive museum in Toyosu, Tokyo. (teamLab, Ephemeral Solidified Light / Photo: teamLab)
In the six months from March to August 2023, the museum has received approximately one million visitors from 182 countries and regions outside of Japan. This makes up 70% of the museum’s total number of visitors (*1). It has also been reported that approximately 1 in 10 visitors to Japan from overseas are visiting teamLab Planets (*2).
NEWLY UNVEILED INSTALLATION: EPHEMERAL SOLIDIFIED LIGHT
Inside an immersive artwork that visitors experience by entering the water, countless masses of light float in the air, each one composed of multiple colors. The boundaries of each color are clearly separated as though they are solid. The seemingly solid color separation of the masses of light is not seen in the natural world, and is caused by extreme synchronization. Through self-organization over time, this synchronization phenomenon creates a large ordered structure.
RENEWAL OF ARTWORK SPACES
In The Infinite Crystal Universe, an artwork that creates a three-dimensional sculpture from a collection of light points, visitors can participate in the work using the teamLab app and create the artwork together with other people in the space. By throwing in a star of your choice from the app, a light sculpture is created in front of you, and the space of this work is created by a group of these light sculptures. With the renewal, five new light sculptures have been added to the installation.
An installation filled with spheres of light that change to ambiguous colors through people’s interactions, Expanding Three-dimensional Existence in Transforming Space, and several other artwork spaces have also been renewed, furthering the experience of physically immersing the entire body.
In addition, teamLab Planets, which was originally scheduled to close at the end of 2023, has been extended to the end of 2027 due to the popularity of the museum.
CONCEPT BEHIND TEAMLAB PLANETS
Together with Others, Immerse your Entire Body, Perceive with your Body, and Become One with the World
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
People go barefoot and immerse their entire bodies in the vast artworks together with others. The artworks change under the presence of people, blurring the perception of boundaries between the self and the works. Other people also create change in the artworks, blurring the boundaries between themselves and the works, and creating a continuity between the self, the art, and others.
-----------------------
*1, teamLab Planets Official Website, Ticket Purchasing Data (data obtained from March 1st - Aug 31st, 2023)
*2 “Amazing Nippon / Digital Art Museum in Tokyo Enchants Overseas Tourists - The Japan News” The Japan News by the Yomiuri Shimbun. August 5, 2023.
About the Museum
teamLab Planets TOKYO DMM
6-1-16 Toyosu, Koto-ku, Tokyo
https://www.teamlab.art/e/planets/
Hours
September - November: 09:00 - 22:00
*Last entry 1 hour before closing
*Hours are subject to change. Please check the official website for the latest information.
Closed: September 6th (Wed), October 4th (Wed), November 8th (Wed)
Admission
Adult (18 years and over): 3,800 JPY
Student (13 - 17 years): 2,300 JPY
Child (4 - 12 years): 1,300 JPY
3 years and under: Free
Disability discount: 1,900 JPY
Official Ticket Store
https://teamlabplanets.dmm.com
Food & Shop
Vegan Ramen UZU Tokyo: https://vegan-uzu.com/pages/uzu-tokyo-en
teamLab Flower Shop: https://www.teamlab.art/e/flowershop/
For Media
Press Kit: https://goo.gl/tQXMLm
Highlight Video: https://youtu.be/KAQMAzRjoH0
About PLANETS Co., Ltd.
Established in 2017. Operates and manages the facilities of teamLab Planets TOKYO.
Location: Tokyo Nihonbashi Tower 10F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Representative: Takumi Nomoto
About teamLab
teamLab (f. 2001) is an international art collective. Their collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world. Through art, the interdisciplinary group of specialists, including artists, programmers, engineers, CG animators, mathematicians, and architects, aims to explore the relationship between the self and the world, and new forms of perception.
In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perceptions of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab exhibitions have been held in cities worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, and Melbourne among others. teamLab museums and large-scale permanent exhibitions include teamLab Borderless and teamLab Planets in Tokyo, teamLab Borderless Shanghai, teamLab SuperNature Macao, and teamLab Massless Beijing, with more to open in cities including Abu Dhabi, Hamburg, Jeddah, and Utrecht.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki, among others.
teamLab is represented by Pace Gallery, Martin Browne Contemporary, and Ikkan Art.
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830716639/en/
Contact information
PLANETS Co., Ltd. Public Relations Department
E-mail: pr-info@planets.art
Interview: https://forms.gle/fAtnDKLpQKFME6XR9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom